Otonomy to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update

Rhea-AI Summary

Otonomy, Inc. (Nasdaq: OTIC) will announce its financial results for the fourth quarter and full year 2021 on February 28, 2022, at 4:30 p.m. ET. The company specializes in developing innovative therapeutics for neurotology, focusing on sustained drug delivery for conditions like hearing loss and tinnitus. Interested parties can join the live call by dialing the provided numbers or access a webcast on Otonomy's website. This event will include a corporate update on the company’s developments in the biopharmaceutical sector.

Positive

• Upcoming announcement of Q4 and full year 2021 financial results may provide insights into business performance.
• Focus on innovative therapeutics in neurotology could indicate potential for growth in a niche market.

Negative

• None.

SAN DIEGO, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the fourth quarter and full year 2021 and provide a corporate update at 4:30 p.m. ET on February 28, 2022.

The live call may be accessed by dialing (877) 305-6769 for domestic callers and (678) 562-4239 for international callers with conference ID code number: 5169343. A live webcast of the call will be available online in the investor relations section of Otonomy’s website at www.otonomy.com and will be archived there for 30 days.

About Otonomy

Otonomy is a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology. The company pioneered the application of drug delivery technology to the ear in order to develop products that achieve sustained drug exposure from a single local administration. This approach is covered by a broad patent estate and is being utilized to develop a pipeline of products addressing important unmet medical needs with a focus on hearing loss and tinnitus. For additional information, please visit www.otonomy.com.

Contacts:

Media Inquiries:
Spectrum Science
Cate Cullen
Account Director
205.910.4443
ccullen@spectrumscience.com

Investor Inquiries:
Westwicke ICR
Robert H. Uhl
Managing Director
858.356.5932
robert.uhl@westwicke.com

FAQ

When is Otonomy reporting its financial results for 2021?

Otonomy will report its financial results for the fourth quarter and full year 2021 on February 28, 2022, at 4:30 p.m. ET.

How can I listen to Otonomy's financial results call?

You can access the call by dialing (877) 305-6769 for domestic or (678) 562-4239 for international callers, using conference ID 5169343.

What company focuses does Otonomy specialize in?

Otonomy specializes in developing therapeutics for neurotology, focusing on hearing loss and tinnitus treatments.

Where can I find the webcast of Otonomy's financial results?

The webcast of Otonomy's financial results will be available on their investor relations section at www.otonomy.com.